Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIC135
- Development stage
- Preclinical
- Lead developer
- University Hospital Tübingen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MIC135 is a modified immunocytokine (MIC) designed for the treatment of acute myeloid leukemia (AML). It consists of an Fc-optimized monoclonal antibody targeting CD135 (also known as Fms-like tyrosine kinase 3 or FLT3) fused to a mutated version of interleukin-15 (IL-15). The IL-15 component is engineered with abolished binding to the IL-15 receptor alpha (IL-15Rα), a modification intended to prevent non-specific systemic immune activation and reduce off-target toxicity. The therapeutic mechanism relies on the antibody portion to tether the cytokine to CD135-expressing leukemic cells, where it can then trans-present the IL-15 to stimulate the IL-15 receptor beta/gamma (IL-15Rβγ) on natural killer (NK) cells. This localized activation induces target-restricted NK cell proliferation and enhances antibody-dependent cellular cytotoxicity (ADCC) against AML cells while sparing healthy tissues.
- Other names
- anti-CD135 immunocytokineanti-CD-135 immunocytokineanti-CD 135 immunocytokineFLT3-IL-15 immunocytokineFLT-3-IL-15 immunocytokineFLT 3-IL-15 immunocytokine
02
Targets
IL2RG (Interleukin-2 receptor gamma subunit)FLT3 (Fms related receptor tyrosine kinase 3)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on MIC135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIC135.